MAP4K4-IN-3 (Compound 17) is a potent and selectiveMAP4K4inhibitor with anIC₅₀of 14.9 nM in kinase assay, anIC₅₀of 470 nM in cell assay. Antidiabetic agent^[1].

MAP4K4, a serine/threonine protein kinase may be a viable target for antidiabetic agents^[1].

Oral dosing in telemetered rats for 5 days with MAP4K4-IN-3 (Compound 2; 25 mg/kg, b.i.d.) results in a number of adverse effects. Substantial weight losses (7%) and body temperature increases (0.4℃) relative to controls are observed over the course of the study. For cardiovascular end points, maximal heart rate increases of 25 bpm, relative to controls, are induced by treatment with MAP4K4-IN-3^[2].

297.74

Solid

C₁₅H₁₂ClN₅

1811510-58-3

Room temperature in continental US; may vary elsewhere.

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

DMSO : 10 mg/mL(33.59 mM;ultrasonic and warming and heat to 60℃)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。